^
No biomarker
Prostate Cancer
enzalutamide
Sensitive
:
A1
PharmaTimes -
No biomarker
Urothelial Cancer
avelumab
Sensitive
:
A1
Pharmafile - 2d
PALB2 mutation
Pancreatic Cancer
rucaparib
Sensitive
:
C2
J Clin Oncol - 2d
EGFR mutation + PD-L1 overexpression
NSCLC
EGFR inhibitor
Sensitive
:
C3
World J Surg Oncol - 4d
No biomarker
NSCLC
durvalumab + CP-675206
Sensitive
:
B
AstraZeneca Press Release - 5d
BRCA2 mutation
Solid Tumor
Immunotherapy
Sensitive
:
C1
JAMA - 5d
KDR C482R
Clear Cell Renal Cell Carcinoma
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 5d
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 5d
MET N375S
Salivary Gland Cancer
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 5d
BRCA2 mutation + TMB-L
Solid Tumor
Immunotherapy
Sensitive
:
C3
JAMA Netw Open - 5d
STRN-ALK fusion
NSCLC
crizotinib
Sensitive
:
C4
Thorac Cancer - 5d
EGFR exon 19 deletion + T790M + C797S + HER-2 amplification
LUAD
afatinib + rivoceranib
Sensitive
:
C4
Onco Targets Ther - 5d
STRN-ALK fusion
NSCLC
alectinib
Resistant
:
C4
Thorac Cancer - 5d
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A1
Merck (MSD) Press Release - 6d
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive
:
B
Merck (MSD) Press Release - 6d
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
J Clin Oncol - 1wk
No biomarker
Urothelial Cancer
nivolumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1wk
EGFR mutation
NSCLC
EGFR inhibitor
Sensitive
:
A2
Oncol Res Treat - 1wk
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive
:
A2
ESMO-BC 2021 - 1wk
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive
:
B
ESMO-BC 2021 - 1wk
HIF1A overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive
:
B
ESMO-BC 2021 - 1wk
BACH1 overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive
:
B
ESMO-BC 2021 - 1wk
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive
:
C2
ESMO-BC 2021 - 1wk
ER positive
HER2 Negative Breast Cancer
ribociclib
Sensitive
:
C2
ESMO-BC 2021 - 1wk
HR positive
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive
:
C2
ESMO-BC 2021 - 1wk
HER-2 positive
Solid Tumor
RC48
Sensitive
:
C2
Gastric Cancer - 1wk
CIP2A-H
CML
dasatinib
Resistant
:
C3
Cancers (Basel) - 1wk
dMMR/MSI-H + TMB-L
Pancreatic Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Pancreatic Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
FOLR1 expression
Solid Tumor
MORAB-202
Sensitive
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive
:
C3
ESMO-BC 2021 - 1wk
ER positive + PGR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive
:
C3
ESMO-BC 2021 - 1wk
HER-2 positive
Gastric Cancer
RC48
Sensitive
:
C3
Gastric Cancer - 1wk
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive
:
C3
J Clin Oncol - 1wk
CIP2A-H
CML
imatinib
Resistant
:
C3
Cancers (Basel) - 1wk
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + alpelisib + LJM-716
Sensitive
:
C3
Clin Cancer Res - 1wk
BRAF V600K + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive
:
C3
Clin Cancer Res - 1wk
BRAF V600E + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive
:
C3
Clin Cancer Res - 1wk
RAD51 overexpression
Ovarian Cancer
PARP inhibitor
Resistant
:
C3
Cancer Cell Int - 1wk
NF2 mutation
Kidney Medullary Carcinoma
bevacizumab + erlotinib
Sensitive
:
C4
Cancers (Basel) - 1wk
NTRK1-KHDRBS1 fusion
Sarcoma
crizotinib
Sensitive
:
C4
World J Surg Oncol - 1wk
MYC underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
HER-2 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
FOXA1 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
MIA underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT5 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
CDH3 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT17 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
SFRP1 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
CXXC5 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
GPR160 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
MLPH overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
GRB7 overexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
KRT14 underexpression
Breast Cancer
ribociclib
Sensitive
:
D
ESMO-BC 2021 - 1wk
ARAF mutation + NRAS mutation
Melanoma
HM95573
Resistant
:
D
Nature - 1wk
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
azacitidine oral
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 2wk
No biomarker
AML
venetoclax
Sensitive
:
A1
Roche Press Release - 2wk
No biomarker
CLL
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 2wk
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 2wk
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
N Engl J Med - 2wk
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive
:
A1
FDA - 2wk
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
NICE - 2wk
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
Cervical Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
Ovarian Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
CRC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
EGFR mutation
NSCLC
osimertinib
Sensitive
:
A2
Asia Pac J Clin Oncol - 2wk
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
Int J Clin Oncol - 2wk
No biomarker
Peritoneal Cancer
bevacizumab + olaparib
Sensitive
:
A2
NICE - 2wk
No biomarker
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive
:
A2
NICE - 2wk
No biomarker
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A2
NICE - 2wk
EGFR exon 20 insertion
NSCLC
TAK-788
Sensitive
:
B
Takeda Press Release - 2wk
CRLF2 rearrangement
ALL
ruxolitinib
Sensitive
:
C2
Leukemia - 2wk
EGFR G719A
NSCLC
dacomitinib
Sensitive
:
C2
J Clin Oncol - 2wk
HER-2 overexpression + PTEN deletion
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Resistant
:
C3
Sci Rep - 2wk
IDH2 mutation + SRSF2 mutation
AML
venetoclax
Sensitive
:
C3
Blood Adv - 2wk
NRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
KRAS mutation + U2AF1 mutation
AML
venetoclax
Resistant
:
C3
Blood Adv - 2wk
BTLA-H
Solid Tumor
Immunotherapy
Resistant
:
C3
Int J Cancer - 2wk
CALR elevation
NSCLC
docetaxel
Sensitive
:
C3
Lung Cancer - 2wk
CALR elevation
NSCLC
pemetrexed
Sensitive
:
C3
Lung Cancer - 2wk
CALR elevation + EGFR mutation
NSCLC
osimertinib
Sensitive
:
C3
Lung Cancer - 2wk
EGFR T790M + C797S
LUAD
gefitinib + osimertinib
Resistant
:
C4
Onco Targets Ther - 2wk
EGFR T790M + C797S
LUAD
osimertinib + anlotinib
Sensitive
:
C4
Onco Targets Ther - 2wk
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant
:
C4
The Oncologist - 2wk
BRCA1 mutation + TP53 R248Q
Cervical Cancer
bevacizumab + olaparib
Sensitive
:
C4
J Med Case Rep - 2wk
GPRC5D overexpression
Multiple Myeloma
JNJ-64407564
Sensitive
:
D
Blood Adv - 2wk
CD276 overexpression
Triple Negative Breast Cancer
B7H3-targeted CAR-T immunotherapy
Sensitive
:
D
ASGCT 2021 - 2wk
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive
:
A1
Sanofi Press Release - 3wk
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive
:
A2
J Clin Oncol - 3wk
HER-2 positive
HER2 Positive Breast Cancer
TCH
Sensitive
:
A2
Ther Adv Med Oncol - 3wk
EGFR mutation
NSCLC
erlotinib + ramucirumab
Sensitive
:
A2
Cancer Treat Res Commun - 3wk
FGFR2b overexpression + HER2 negative
Gastric Cancer
FPA-144
Sensitive
:
B
Amgen Press Release - 3wk
FGFR2b overexpression + HER2 negative
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive
:
B
Amgen Press Release - 3wk
No biomarker
Multiple Myeloma
ALLO-715
Sensitive
:
B
Allogene Therapeutics Press Release - 3wk
BRAF V600E
Melanoma
nivolumab + ipilimumab
Sensitive
:
C2
EADO-WCM 2021 - 3wk
FLT3-ITD mutation
AML
quizartinib
Sensitive
:
C2
Haematologica - 3wk
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + TAK-228
Sensitive
:
C2
Breast Cancer Res Treat - 3wk
OLR1 overexpression
NSCLC
Immunotherapy
Sensitive
:
C3
Front Oncol - 3wk
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive
:
C3
Am J Cancer Res - 3wk
BRAF mutation
NSCLC
PD-L1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
EGFR exon 19 deletion
NSCLC
EGFR inhibitor
Sensitive
:
C3
Future Oncol - 3wk
BRAF mutation
NSCLC
PD1 inhibitor
Sensitive
:
C3
Eur J Cancer - 3wk
RB1 mutation + TP53 mutation
Urothelial Cancer
atezolizumab
Sensitive
:
C3
BMC Cancer - 3wk
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive
:
C3
NPJ Breast Cancer - 3wk
CCNE1 overexpression
Ovarian Cancer
AZD1775
Sensitive
:
C3
Clin Cancer Res - 3wk
CCNE1 overexpression
Endometrial Cancer
AZD1775
Sensitive
:
C3
Clin Cancer Res - 3wk
XAGE1 antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
CTAG1B antibody elevation + XAGE1 antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
CTAG1B antibody elevation
NSCLC
Immunotherapy
Sensitive
:
C3
Clin Chim Acta - 3wk
ASS1 negative
HCC
BCT-100
Sensitive
:
C3
Invest New Drugs - 3wk
RAD52 underexpression
Bladder Cancer
cisplatin
Resistant
:
C3
Int J Mol Sci - 3wk
BRAF V600E
Melanoma
Immunotherapy
Resistant
:
C3
SID 2021 - 3wk
HER-2 amplification
LUAD
pembrolizumab
Sensitive
:
C4
Front Oncol - 3wk
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive
:
C4
Onco Targets Ther - 3wk
WEE1 mutation + PKMYT1 overexpression
Solid Tumor
AZD1775
Resistant
:
C4
Clin Cancer Res - 3wk
NRAS Q61R
Melanoma
nivolumab + ipilimumab
Sensitive
:
C4
EADO-WCM 2021 - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
camrelizumab
Resistant
:
C4
BMC Pulm Med - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
larotrectinib
Sensitive
:
C4
BMC Pulm Med - 3wk
BRCA1 S451Lfs*20
Gallbladder Cancer
olaparib
Sensitive
:
C4
Onco Targets Ther - 3wk
CD20 underexpression
Multiple Myeloma
lenalidomide
Resistant
:
D
Onco Targets Ther - 3wk
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
sunitinib
Sensitive
:
D
Transl Oncol - 3wk
BRAF V600E
Melanoma
encorafenib + S63845
Sensitive
:
D
EADO-WCM 2021 - 3wk
NGFR overexpression
Squamous Cell Skin Cancer
5-fluorouracil
Sensitive
:
D
SID 2021 - 3wk
NGFR overexpression
Squamous Cell Skin Cancer
cisplatin
Sensitive
:
D
SID 2021 - 3wk
NRAS mutation
Melanoma
binimetinib + encorafenib
Sensitive
:
D
EADO-WCM 2021 - 3wk
CD20 underexpression
Multiple Myeloma
elotuzumab
Resistant
:
D
Onco Targets Ther - 3wk
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
crizotinib + sunitinib
Sensitive
:
D
Transl Oncol - 3wk
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
crizotinib
Resistant
:
D
Transl Oncol - 3wk
NEIL3 deletion
Prostate Cancer
enzalutamide
Resistant
:
D
Int J Mol Sci - 3wk
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive
:
C1
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive
:
C1
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive
:
C1
No biomarker
NSCLC
ramucirumab
Sensitive
:
A1
ALK positive
NSCLC
lorlatinib
Sensitive
:
C1
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive
:
C1
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
C1
EGFR L858R
NSCLC
afatinib
Sensitive
:
C1
EGFR T790M
NSCLC
osimertinib
Sensitive
:
C1
No biomarker
NSCLC
durvalumab
Sensitive
:
A1
ALK positive
NSCLC
alectinib
Sensitive
:
C1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive
:
C1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive
:
C1
KIT positive
GIST
imatinib
Sensitive
:
C1
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive
:
C1
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
NSCLC
pembrolizumab
Sensitive
:
C1
ALK fusion
NSCLC
brigatinib
Sensitive
:
C1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
C1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our